Five Prime Therapeutics Announces Resignation of Dr. Lewis T. “Rusty” Williams From Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced that the company’s founder, Lewis T. "Rusty" Williams, M.D., Ph.D., has resigned as a member of the Five Prime Board of Directors to focus on his role as Chief Executive Officer of Walking Fish Therapeutics, a start-up company that he co-founded, and other activities supporting life science start-up companies.